Citations

Clear

3030 citation(s) found for "Susan, M".

Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes
Waller, Rosalie, McKay, James , Clay‐Gilmour, Alyssa , Wei, Xiaomu , Madsen, Michael J. , Sborov, Douglas W. , Curtin, Karen , Slager, Susan L, Offit, Kenneth , Vachon, Celine M. , Lipkin, Steven M. , Camp, Nicola J. , Waller, Rosalie G. , Griffin, R. L. , Clay-Gilmour, Alyssa, Waller, Rosalie G , Griffin, Rosalie , Klein, Robert J. , Vijai, Joseph , Vachon, Celine M. , Dumontet, Charles

Mayo Clinic

Human Molecular Genetics | March 2, 2021 | Volume: 30 | Issue: 12 | Pages: 1142-1153

10.1093/hmg/ddab066 | PMID 33751038 Get It

Abstract Inherited genetic risk factors play a role in multiple myeloma (MM), yet considerable missing heritability exists. Rare risk variants at genome-wide association study (GWAS) loci are a new avenue to explore. Pleiotropy between lymphoid neoplasms (LNs) has been suggested in family history and genetic studies, but no studies have interrogated sequencing for pleiotropic genes or rare risk variants. Sequencing genetically enriched cases can help discover rarer variants. We analyzed exome sequencing in familial or early-onset MM cases to identify rare, functionally relevant variants near GWAS loci for a range of LNs. A total of 149 distinct and significant LN GWAS loci have been published. We identified six recurrent, rare, potentially deleterious variants within 5 kb of significant GWAS single nucleotide polymorphisms in 75 MM cases. Mutations were observed in BTNL2, EOMES, TNFRSF13B, IRF8, ACOXL and TSPAN32. All six genes replicated in an independent set of 255 early-onset MM or familial MM or precursor cases. Expansion of our analyses to the full length of these six genes resulted in a list of 39 rare and deleterious variants, seven of which segregated in MM families. Three genes also had significant rare variant burden in 733 sporadic MM cases compared with 935 control individuals: IRF8 (P = 1.0 × 10−6), EOMES (P = 6.0 × 10−6) and BTNL2 (P = 2.1 × 10−3). Together, our results implicate six genes in MM risk, provide support for genetic pleiotropy between LN subtypes and demonstrate the utility of sequencing genetically enriched cases to identify functionally relevant variants near GWAS loci.
Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma
Liebow, Mark , Thompson, Carrie A. , Nowakowski, Grzegorz S. , Call, Timothy G. , Macon, William R. , Cerhan, James R. , Cerhan, James R , Larson, Melissa C. , Kay, Neil E. , Habermann, Thomas M. , Slager, Susan L.

Mayo Clinic

International Journal of Cancer | March 1, 2021 | Volume: 149 | Issue: 3 | Pages: 535-545

10.1002/ijc.33541 | PMID 33644854 Get It

AbstractNon‐steroidal anti‐inflammatory drugs (NSAIDs) and statin drugs may protect against the development of non‐Hodgkin lymphoma (NHL), but data are limited, particularly for NHL subtypes. Furthermore, some in vitro, animal and epidemiologic data suggest there may be a synergistic effect of these two agents, but there has been no test of this hypothesis in NHL. We evaluated the self‐reported use of NSAIDs and statins in a clinic‐based study of 1703 NHL patients and 2199 frequency‐matched controls. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for potential confounding variables. We observed an inverse association of regular use of low‐dose aspirin with risk of NHL (OR = 0.82; 95% CI 0.70‐0.96) that was stronger with longer duration of use (P < .01). There were no associations for use of regular or extra‐strength aspirin, ibuprofen, other NSAIDs, statins or other cholesterol‐lowering drugs with NHL risk, while an inverse association with COX‐2 inhibitors was equivocal. There was also no interaction of low‐dose aspirin and statins on NHL risk. Inverse associations of similar magnitude to all NHL were observed for regular use of low‐dose aspirin with diffuse large B‐cell, follicular, marginal zone and all other lymphomas, although not all associations were statistically significant. In conclusion, low‐dose aspirin but not regular/extra strength aspirin, other NSAIDs or statin use was associated with lower risk of NHL. Beyond the potential for the primary prevention of NHL, these data also point to a role of anti‐platelet or other effects of low‐dose aspirin in lymphomagenesis that warrant follow‐up.
Perinatal Mood and Anxiety Disorder Management in Multicenter Community Practices: Clinicians’ Training, Current Practices and Perceived Strategies to Improve Future Implementation
Puspitasari, Ajeng J. , Heredia, Dagoberto , Weber, Elise, Betcher, Hannah K. , Brodrick, Ellen M., Skinner, Susan M., Tomlinson, Angie L., Salik, Shana S., Allen, Summer V. , O'Grady, J. , Johnson, Emily K. , L’amoureux, Tayler M., Moore, Katherine M. , O'Grady, Jason S , Johnson, Emily K , Coombes, Brandon J.

Mayo Clinic

Journal of Primary Care & Community Health | February 23, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/2150132721996888 | PMID 33618558 Get It

Background: This study aimed to explore clinicians’ perspectives on the current practice of perinatal mood and anxiety disorder (PMAD) management and strategies to improve future implementation. Methods: This study had a cross-sectional, descriptive design. A 35-item electronic survey was sent to clinicians (N = 118) who treated perinatal women and practiced at several community clinics at an academic medical center in the United States. Results: Among clinicians who provided care for perinatal women, 34.7% reported never receiving PMAD management training and 66.3% had less than 10 years of experience. Out of 10 patients who reported psychiatric symptoms, 47.8% of clinicians on average reported providing PMAD management to 1 to 3 patients and 40.7% noted that they conducted screening only when patient expresses PMAD symptoms. Suggested future improvements were providing training, developing a referral list, and establishing integrated behavioral health services. Conclusions: Results from this study indicated that while PMAD screening and management was implemented, improvements are warranted to meet established guidelines. Additionally, clinicians endorsed providing PMAD management to a small percentage of perinatal patients. Suggested strategies to increase adoption and implementation of PMAD management should be explored to improve access to behavioral health services for perinatal women.
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment
Mrugała, Maciej M. , Pressley, Shelley M., Taylor, Jennie , Thomas, Alissa A. , Wefel, Jeffrey S. , Acquaye, Alvina , Haynes, Chas, Agnihotri, Sameer , Lim, Michael , Peters, Katherine B. , Sulman, Erik P. , Salcido, Joanne, Butowski, Nicholas , Hervey‐Jumper, Shawn L. , Mansouri, Alireza , Oliver, Kathy , Porter, Alyx B. , Nassiri, Farshad , Schiff, David , Dunbar, Erin, Hegi, Monika E. , Bent, Martin J. van den , Chang, Susan M. , Zadeh, Gelareh , Chheda, Milan G. , Wefel, Jeffrey S , Peters, Katherine B , Mansouri, Alireza , Armstrong, Terri S , van den Bent, Martin J , Zadeh, Gelareh , Chheda, Milan G , Sulman, Erik P , Ostrom, Quinn T. , Coven, Scott L. , Armstrong, Terri S. , Chang, Susan Marina

Mayo Clinic

Neuro-Oncology Advances | February 21, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdab035 | PMID 34007966 Get It

AbstractBackgroundIt remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, training, and research efforts.MethodsWe performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology organizations across 6 continents, April 24–May 17, 2020. We assessed clinical practice and research environments, institutional preparedness and support, and perceived impact on patients.ResultsOf 582 respondents, 258 (45%) were US-based and 314 (55%) international. Ninety-four percent of participants reported changes in their clinical practice. Ninety-five percent of respondents converted at least some practice to telemedicine. Ten percent of practitioners felt the need to see patients in person, specifically because of billing concerns and pressure from their institutions. Sixty-seven percent of practitioners suspended enrollment for at least one clinical trial, including 62% suspending phase III trial enrollments. More than 50% believed neuro-oncology patients were at increased risk for COVID-19. Seventy-one percent of clinicians feared for their own personal safety or that of their families, specifically because of their clinical duties; 20% had inadequate personal protective equipment. While 69% reported increased stress, 44% received no psychosocial support from their institutions. Thirty-seven percent had salary reductions and 63% of researchers temporarily closed their laboratories. However, the pandemic created positive changes in perceived patient satisfaction, communication quality, and technology use to deliver care and mediate interactions with other practitioners.ConclusionsThe pandemic has changed treatment schedules and limited investigational treatment options. Institutional lack of support created clinician and researcher anxiety. Communication with patients was satisfactory. We make recommendations to guide clinical and scientific infrastructure moving forward and address the personal challenges of providers and researchers.
Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members
Ensign, Shannon P. Fortin , Hrachova, Maya , Chang, Susan M. , Mrugała, Maciej M. , Ensign, Shannon P. Fortin

Mayo Clinic

Neuro-Oncology Practice | February 20, 2021 | Volume: 8 | Issue: 3 | Pages: 310-316

10.1093/nop/npab003 | PMID 34055378 Get It

AbstractBackgroundMolecular testing (MT) is utilized in neuro-oncology with increasing frequency. The aim of this study was to determine clinical practice patterns to acquire this information, interpret and utilize MT for patient care, and identify unmet needs in the practical clinical application of MT.MethodsWe conducted a voluntary online survey of providers within the Society for Neuro-Oncology (SNO) membership database between March and April 2019.ResultsWe received 152 responses out of 2022 SNO members (7.5% of membership). 88.8% of respondents routinely order MT for newly diagnosed gliomas. Of those who do not, testing is preferentially performed in younger patients or those with midline tumors. 82.8% use MT in recurrent gliomas. Other common indications included: metastatic tumors, meningioma, and medulloblastoma. Many providers utilize more than one resource (36.0%), most frequently using in-house (41.8%) over commercially available panels. 78.1% used the results for clinical decision-making, with BRAF, EGFR, ALK, and H3K27 mutations most commonly directing treatment decisions. Approximately, half (48.5%) of respondents have molecular tumor boards at their institutions. Respondents would like to see SNO-endorsed guidelines on MT, organized lists of targeted agents available for specific mutations, a database of targetable mutations and clinical trials, and more educational programs on MT.ConclusionThis survey was marked by several limitations including response rate and interpretation of MT. Among respondents, there is routine use of MT in Neuro-Oncology, however, there remains a need for increased guidance for providers to effectively incorporate the expanding genomic data resulting from MT into daily Neuro-Oncology practice.
Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer
Besson, Caroline , Moore, Amy , Wu, Wenting , Vajdic, Claire M. , Sanjosé, Sílvia de, Camp, Nicola J. , Smedby, Karin E. , Morton, Lindsay M. , Brewer, Jerry D., Han, Jiali , Berndt, Sonja I. , Link, Brian K. , Wang, Sophia , Staines, Anthony , Melbye, Mads , Diver, W. Ryan , Vermeulen, Roel , Kleinstern, Geffen , Clavel, Jacqueline , Miligi, Lucia , Cerhan, James R , Han, Jiali , Link, Brian K , Vajdic, Claire M , Morton, Lindsay M , Wang, Sophia S , Clavel, Jacqueline , Shanafelt, Tait D. , Zablotska, Lydia B. , Engels, Eric A. , Cerhan, James R. , Slager, Susan L.

Mayo Clinic

International Journal of Epidemiology | February 19, 2021 | Volume: 50 | Issue: 4 | Pages: 1325-1334

10.1093/ije/dyab042 | PMID 33748835 Get It

AbstractBackgroundEpidemiological studies have demonstrated a positive association between chronic lymphocytic leukaemia (CLL) and non-melanoma skin cancer (NMSC). We hypothesized that shared genetic risk factors between CLL and NMSC could contribute to the association observed between these diseases.MethodsWe examined the association between (i) established NMSC susceptibility loci and CLL risk in a meta-analysis including 3100 CLL cases and 7667 controls and (ii) established CLL loci and NMSC risk in a study of 4242 basal cell carcinoma (BCC) cases, 825 squamous cell carcinoma (SCC) cases and 12802 controls. Polygenic risk scores (PRS) for CLL, BCC and SCC were constructed using established loci. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).ResultsHigher CLL-PRS was associated with increased BCC risk (OR4th-quartile-vs-1st-quartile = 1.13, 95% CI: 1.02–1.24, Ptrend = 0.009), even after removing the shared 6p25.3 locus. No association was observed with BCC-PRS and CLL risk (Ptrend = 0.68). These findings support a contributory role for CLL in BCC risk, but not for BCC in CLL risk. Increased CLL risk was observed with higher SCC-PRS (OR4th-quartile-vs-1st-quartile = 1.22, 95% CI: 1.08–1.38, Ptrend = 1.36 × 10–5), which was driven by shared genetic susceptibility at the 6p25.3 locus.ConclusionThese findings highlight the role of pleiotropy regarding the pathogenesis of CLL and NMSC and shows that a single pleiotropic locus, 6p25.3, drives the observed association between genetic susceptibility to SCC and increased CLL risk. The study also provides evidence that genetic susceptibility for CLL increases BCC risk.
Closing the Mentorship Gap: Implementation of Speed Mentoring Events for Women Faculty and Trainees in Anesthesiology
Pollard, E. Morgan, Gali, Bhargavi , Moeschler, Susan M. , Sharpe, Emily E.

Mayo Clinic

Women's Health Reports | February 18, 2021 | Volume: 2 | Issue: 1 | Pages: No page available

10.1089/whr.2020.0095 | PMID 33786528 Get It

Introduction: Mentorship is a key component to success in academic medicine. Women are under-represented in leadership positions within medicine. Women are less likely to identify mentors than men. Speed mentoring is an innovative strategy to facilitate mentorship in academic medicine. Materials and Methods: A speed mentoring event for women faculty members in an academic anesthesiology department was held, followed by a second event for trainees. Attendees completed surveys about mentorship experiences at baseline and in follow-up. Questions were rated on a 7-point Likert scale with 1 = strongly disagree and 7 = strongly agree with values reported as median (1st, 3rd quartile). Results: Baseline surveys indicated poor satisfaction with mentoring in the prior 6 months as 4.5 (3, 5.25). Twelve months later, mentees reported increased satisfaction with mentoring 6 (6, 6). Mentors and mentees felt their time was well spent during both events. There was an increase in the number of mentors identified after the events by both groups. Conclusions: Our results suggest speed mentoring is well received and impactful with minimal time and monetary investment. The attendees of the events identified an increased number of mentors after speed mentoring events, and this effect was maintained at 6–12 months. Speed mentoring may be one path to providing support for women to advance their careers in academic medicine. More research is warranted to better evaluate effectiveness of formats such as speed mentoring to facilitate improved mentorship for women in academic anesthesiology.
Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative
Dirven, Linda , Vos, Maartje E, Walbert, Tobias , Arons, David, Bent, Martin J. van den , Brown, Paul D. , Chang, Susan M. , Coens, Corneel , Grant, Robin, Jalali, Rakesh , Leach, Danielle, Mendoza, Tito R. , Nayak, Lakshmi , Oliver, Kathy , Reijneveld, Jaap C. , Wen, Patrick Y. , Taphoorn, Martin , Mendoza, Tito , Weller, Michael , van den Bent, Martin J , Armstrong, Terri S. , Blakeley, Jaishri O. , Bulbeck, Helen , Gilbert, Mark R. , Leeper, Heather , Rhun, Émilie Le , Rubinstein, Larry , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology Practice | February 14, 2021 | Volume: 8 | Issue: 4 | Pages: 417-425

10.1093/nop/npab013 | PMID 34277020 Get It

Abstract Background The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high quality, both in terms of relevance and other measurement properties. This systematic review aimed to identify PRO measures that have been used in brain tumor studies to date. Methods A systematic literature search for articles published up to June 25, 2020 was conducted in several electronic databases. Pre-specified inclusion criteria were used to identify studies using PRO measures assessing symptoms, (instrumental) activities of daily living [(I)ADL] or health-related quality of life (HRQoL) in adult patients with glioma, meningioma, primary central nervous system lymphoma, or brain metastasis. Results A total of 215 different PRO measures were identified in 571 published and 194 unpublished studies. The identified PRO measures include brain tumor-specific, cancer-specific, and generic instruments, as well as instruments designed for other indications or multi- or single-item study-specific questionnaires. The most frequently used instruments were the EORTC QLQ-C30 and QLQ-BN20 (n = 286 and n = 247), and the FACT-Br (n = 167), however, the majority of the instruments were used only once or twice (150/215). Conclusion Many different PRO measures assessing symptoms, (I)ADL or HRQoL have been used in brain tumor studies to date. Future research should clarify whether these instruments or their scales/items exhibit good content validity and other measurement properties for use in brain tumor patients.
The Path to ‘Dieps by Dinner’ Involves The Entire Operative Team
Lindén, Anna , Harless, Christin A., Nguyen, Minh-Doan T. , Law, Katherine E. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | February 13, 2021 | Volume: 64 | Issue: 1 | Pages: 646-650

10.1177/1071181320641147 Get It

More and more breast cancer patients are turning to autologous options for reconstruction. Deep Inferior Epigastric Perforator (DIEP) flap reconstruction is considered the gold standard flap breast reconstruction procedure; however, it requires a significant number of resources, including two surgeons and microsurgical equipment. A multidisciplinary group was tasked with reducing operative time of DIEP flap procedures by 25% so that complex surgeries can become more routine and accessible to patients. Using participatory ergonomics, members of the operative team were engaged to identify interventions. Following implementation, 22 DIEP flap cases were evaluated using workload surveys and patient outcomes to determine the success of the interventions. DIEP flap surgical durations were reduced by 25% on average (M=12.9 hours, SD=5.7 to M=9.7 hours, SD=1.4). When cases lasted longer than 9 hours, surgeons reported 31% more physical demand and 78% more fatigue than cases that were 9 hours or less. Survey results linked positive team characteristics to reduced frustrations and distractions.
Surgeon Postures during Deep Inferior Epigastric Perforator Flap Breast Reconstruction Procedures: A Pilot Study
Wang, Tianke , Harless, Christin A., Nguyen, Minh-Doan T. , Law, Katherine E. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | February 13, 2021 | Volume: 64 | Issue: 1 | Pages: 632-633

10.1177/1071181320641143 Get It

Deep inferior epigastric perforator (DIEP) flap is a surgical procedure using tissue harvested from the abdominal area to reconstruct the breast after a mastectomy. Primary surgical phases include the abdominal flap harvest, chest dissection, and anastomosis. In this study, inertial measurement units (IMUs) were used to measure surgeon upper body postures while performing DIEP flap procedures. Ergonomic risks of musculoskeletal disorders were evaluated using the Rapid Upper Limb Assessment (RULA) based on the postures obtained from the IMUs. Joint angles were analyzed using a one-way ANOVA. The neck and back had higher joint angles during the abdominal flap (M=32°, 17°, respectively) and chest dissection (M=31°, 18°, respectively) phases than the anastomosis phase. These high-risk postures may lead to musculoskeletal disorders. Future interventions should focus on improving the postures of the neck and back during the abdominal flap and chest dissection phases of the procedure.